Navigation Links
Celsion Corporation Reports Third Quarter 2013 Financial Results and Provides Business Update
Date:11/12/2013

LAWRENCEVILLE, N.J., Nov. 12, 2013 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the third quarter ended September 30, 2013 and provided an update from its retrospective analysis of the clinical trial results for ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin.  ThermoDox® is being evaluated in a global, multi-center Phase III clinical trial (the HEAT Study) in patients with non-resectable hepatocellular carcinoma (HCC), also known as primary liver cancer.  ThermoDox® is also being evaluated in a Phase II trial for patients with recurrent chest wall breast cancer (the DIGNITY Study).

Financial Results

For the quarter ended September 30, 2013, Celsion reported a net loss of $4.1 million compared to a net loss of $6.0 million in the same period of 2012. Net loss for the quarter ended September 30, 2013 was favorably impacted by lower operating costs ($1.4 million) coupled with a lower non-cash charge ($0.4 million) from the change in valuation of the common stock warrant liability associated with registered direct equity offerings in September 2009 and June 2013.  For the nine month period ended September 30, 2013, Celsion reported a net loss of $4.3 million compared to a net loss of $18.3 million in the same period of 2012.  Net loss for the nine months ended September 30, 2013 was favorably impacted by lower operating costs ($4.4 million) coupled with the non-cash benefit of $8.1 million from the valuation of common stock warrant liability associated with equity financings in September 2009 and June 2013.  The Statement of Operations was also impacted by a non-cash deemed dividend from the beneficial conversion feature of $4.6 million on the preferred stock equity financing announced in February 20
'/>"/>

SOURCE Celsion Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Celsion Corporation to Hold Third Quarter 2013 Financial Results Conference Call on Tuesday, November 12, 2013
2. Celsion Corporation Announces Combined Clinical Data from Two Phase I Trials to be Presented at the 2013 San Antonio Breast Cancer Conference
3. Celsion Corporation Reports Second Quarter 2013 Financial Results and Provides HEAT Study Update
4. Celsion Corporation to Hold Second Quarter 2013 Financial Results Conference Call on Thursday, August 8, 2013
5. Celsion Corporation Issues Statement Regarding Misleading Blog Entry
6. Celsion Corporation Reports Year End 2012 Financial Results and Provides Business Update
7. Celsion Corporation to Hold Year-End 2012 Financial Results Conference Call On Monday, March 18, 2013
8. Unilife Corporation Announces Financial Results For Fiscal Year 2014 First Quarter
9. TechPrecision Corporation Schedules Conference Call to Report Fiscal 2014 Second Quarter Financial Results
10. Luminex Corporation Reports Third Quarter 2013 Results
11. DURECT Corporation Announces Third Quarter 2013 Financial Results and Update of Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 Moms are ready to live the ... and their kids, according to the results of the ... Go Mobile for Moms, the latest installment in BabyCenter,s ... 1 pregnancy and parenting web and mobile destination worldwide, ... moms surveyed say they can,t think of a reason ...
(Date:10/22/2014)... , Oct. 22, 2014  Paper Pak ... has developed APLS ® Body Guard Bio, ... the spread of bacteria and virus while protecting ... Body Guard Bio features a rugged, external nylon ... that create a leak-proof inner chamber that contains ...
(Date:10/22/2014)... , Oct. 22, 2014 AVACEN Medical ... device received 510 (k) OTC clearance by the U.S. ... 100 to be marketed over the Internet for: ... muscle spasms; and minor strains and sprains . ... The AVACEN 100 (MSRP $2495) is a sophisticated medical ...
Breaking Medicine Technology:BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 2BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 3BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 4New, State-Of-The-Art Body Bag Minimizes The Spread Of Bacteria And Virus 2AVACEN Medical Announces FDA Clearance of First Medical Device with Internal Game Mode 2
... PARSIPPANY, N.J. , Jan. 14 As ... market, the company has announced the addition of three Vice ... these positions bring a deep knowledge of the spine and ... distribution networks in their respective areas.   , Randy ...
... , HORSHAM, Pa. , ... 3 clinical study comparing the efficacy and safety of STELARA™ ... severe plaque psoriasis appear today in The New England ... clinical response with both doses of STELARA than with etanercept ...
Cached Medicine Technology:Custom Spine Announces the Expansion of its Sales Management Team 2STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine 2STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine 3STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine 4STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine 5STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine 6STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine 7STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine 8STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine 9
(Date:10/22/2014)... Best Cheap Hosting USA is among the ... has recently announced that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ) is ... around the world. , “iPower is one of the ... providing various kinds of useful products for new and ... excellent customer service and a number of features which ...
(Date:10/22/2014)... 2014 Richard Carlson, Managing Partner of ... with over 25 years experience. Mr. Carlson is ... areas related to EDI, B2B Commerce, RFID and Internet/Intranet ... Advisory Board member for Pharmaceutical Commerce Magazine and a ... Group is a management and technology consulting firm focused ...
(Date:10/22/2014)... Tara Haelle HealthDay ... Binge drinking among young adult men may lead to increased ... drinking didn,t cause a similar rise in blood pressure for ... In fact, when young adult women drank lightly or moderately, ... the study found. "This finding parallels studies in older ...
(Date:10/20/2014)... Texas (PRWEB) October 20, 2014 The ... the must-have source of thousands of facts, figures and ... countries and 68 medical sector forecast categories the ... with global, regional and national views on the worldwide ... outlook. , The report gives you data for 2010-2019, ...
(Date:10/20/2014)... Women’s health specialist, Dr. Amber Murphy, MD, Ob/Gyn ... Inc., A Division of MaternOhio Clinical Associates, Inc., who ... patients annually. Dr. Murphy will provide a full range ... women’s life. She is accepting new patients at two ... , Dr. Murphy offers a wide variety of services ...
Breaking Medicine News(10 mins):Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 2Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 3
... of Medicare recipients undergoing treatment for retinal conditions nearly ... the types of procedures most commonly performed, according to ... of Ophthalmology , one of the JAMA/Archives journals. ... both age-related macular degeneration (AMD) and diabetic retinopathy account ...
... symptoms associated with cancer symptoms often unrecognized ... of cancers regardless of whether the patient is ... survivor, according to researchers from the Regenstrief Institute ... nursing. Common symptoms include fatigue, pain, weakness, ...
... News) -- Women with epilepsy may be at increased risk of ... included 375 women who planned to have a child, average age ... to 10 years. During the study period, 62 percent of the ... epilepsy was more than twice the 15 percent rate in the ...
... By Steven Reinberg HealthDay Reporter , SUNDAY, Oct. ... to play a role in the propensity for obesity. ... the Oct. 10 online edition of Nature Genetics . ... gene variants linked to obesity and confirmed the involvement of ...
... the receipt of breast cancer care persist despite accounting ... is the conclusion of a study published early online ... American Cancer Society. The findings suggest that greater efforts ... care and to ensure that all affected women receive ...
... , UCSF Chancellor Susan Desmond-Hellmann, MD, MPH, will ... Arts and Sciences, alongside some of the world,s ... Desmond-Hellmann, a renowned oncologist and biotechnology ... biomedical research institution, was among five members of ...
Cached Medicine News:Health News:Treatment of retinal conditions appears to have changed significantly in previous decade 2Health News:Physical symptoms prevalent no matter what stage of cancer including remission 2Health News:Study Sees Link Between Epilepsy, Infertility 2Health News:Researchers Pinpoint Array of Obesity Genes 2Health News:Researchers Pinpoint Array of Obesity Genes 3Health News:Insurance and socioeconomic status do not explain racial disparities in breast cancer care 2Health News:UCSF Chancellor inducted into Academy of Arts and Sciences 2Health News:UCSF Chancellor inducted into Academy of Arts and Sciences 3
Lyphochek Assayed Chemistry Control requires no special diluent and has good reconstituted stability for enzymes and CO2. It is assayed for most major instruments and methodologies....
Lyphochek Benzo/TCA Control Set A is ideal for monitoring HPLC methods for identification and quantitation of benzodiazepines and tricyclic antidepressant drugs....
Lyphochek Benzo/TCA Control Set B is ideal for monitoring HPLC methods for identification and quantitation of benzodiazepines and antidepressant drugs....
Lyphochek Therapeutic Drug Monitoring Control (TDM) contains over 40 analytes with assayed values at three clinically significant levels....
Medicine Products: